You are here

Acelyrin

Acelyrin makes a splash with IPO, biopharma expects to raise $540M

Acelyrin makes a splash with IPO, biopharma expects to raise $540M

Medical Marketing and Media

Flag link:

Acelyrin follows Kenvue with largest IPO for a biotech startup since 2021

Acelyrin follows Kenvue with largest IPO for a biotech startup since 2021

BioPharma Dive

Flag link:

IPO Market Shows Signs of Life as Acelyrin Begins Nasdaq Bid

IPO Market Shows Signs of Life as Acelyrin Begins Nasdaq Bid

BioSpace

Flag link:

AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa

AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa

EP Vantage

hidradenitis suppurativa

Flag link:

Acelyrin raises $250M, licenses antibody drug that could rival Novartis, Lilly meds

Acelyrin raises $250M, licenses antibody drug that could rival Novartis, Lilly meds

MedCity News

monoclonal antibodies

Flag link: